tbuckley/cabot-search huggingface dataset:
논평참조 : 간세포암종 진단에 유의한 PIVKA-II 값의 제시- ROC Curve를 이용하여 -
Authors: 김명진 ( Myong Jin Kim ), 배강우 ( Kang Woo Bae ), 서평주 ( Pyoung Ju Seo ), 정인국 ( In Kook Jeong ), 김정혁 ( Jung Hyuk Kim ), 이보한 ( Bo Han Lee ), 방기태 ( Ki Tae Bang ), 김동우 ( Dong Woo Kim ), 송일한 ( Il Han Song )
Journal: Clinical and Molecular Hepatology (2006)

Background/Aims: Protein induced by vitamin K absence or antagonist-II (PIVKA-II), also known as des-carboxyprothrombin (DCP), can be used as an alternative tool to alpha-fetoprotein (AFP) for surveillance of hepatocellular carcinoma (HCC). The aims of the present study were to compare PIVKA- II levels between the patients with HCC and patients with non-HCC chronic liver disease, to evaluate the correlation of PIVKA-II and AFP in HCC patients, and finally to estimate the optimal cut-off value for PIVKA-II for the diagnosis of HCC with using the receiver operating characteristic (ROC) curve. Methods: A total of 227 consecutive patients with HCC (n=42) or chronic liver disease (n=185) were enrolled in this study. HCC was diagnosed histologically or by imaging such as computed tomography, magnetic resonance imaging or angiography. The serum PIVKA-II and AFP levels were measured by electrochemiluminoimmunoassay with using the Haicatch PIVKA-II kit and by immunoradiometric assay, respectively. Results: The PIVKA-II level in the HCC patients was significantly higher than the non-HCC chronic liver disease patients (903.0±1156.7 vs. 111.7±211.0 mAU/ mL, respectively, P<0.01). PIVKA-II and AFP showed a statistical correlation in HCC patients (r=0.46, P<0.01). The sensitivity and specificity of PIVKA-II for the diagnosis of HCC were 66.7% and 74.1%, respectively, and when tasted together with AFP, the sensitivity was increased by 85.7%. For the ROC curve of PIVKA-II in HCC patients, the specificity of a 250 mAU/mL level of PIVKA-II was 95%. Conclusions: PIVKA-II was as useful surveillance tool for differentiating HCC from chronic liver disease, and a PIVKA-II value of 250 mAU/ mL was proposed as a significant cut-off value for diagnosis of hepatocellular carcinoma.
Press: A register of blunders or botchers?
Authors: J. Smith
Journal: BMJ (2000)

One of the classic tactics of “spin”—telling a story so that listeners hear the message you want to convey—is to preannounce a report and what you are going to do about it a day or two before the report comes out. That way you get your reaction in first, and, because no one else has read the report, the media describe it in your terms.

Alan Milburn, secretary of state for health, is a fine master of spin, and he showed his skills again last week over a report on learning from adverse events in the NHS by Liam Donaldson, England's chief medical officer (see pages 1683 and 1689). In the process, he obscured one of the key lessons for any organisation that is serious about reducing errors.

As An Organisation with a Memory (the report's evocative title) points out, adverse events in the NHS—indeed, any health system—are common. And most of them are not caused by bad individuals: “In the great majority of cases, the causes of serious failures stretch far …
Probe-based confocal laser endomicroscopy in acute lung allograft rejection
Authors: Jonas Yserbyt, Christophe Dooms, Wim Janssens, Geert Verleden, Vincent Ninane, Marc Decramer
Journal: European Respiratory Journal (2011)

Several aspects of normal alveolar tissue in probe-based confocal laser endomicroscopy (pCLE) have been elucidated; a description of the alveoloscopic findings in different pulmonary disorders is still largely lacking.  In a prospective study, we evaluated 40 lung transplant recipients using probe-based confocal laser endomicroscopy (pCLE) preceding BAL and transbronchial lung biopsy (TBLB) during bronchoscopy. In 6 patients (15%) acute rejection (AR) was diagnosed using TBLB. The recordings of the pCLE images were digitally processed and analyzed for the following parameters: alveolar duct diameter, alveolar elastin thickness, macrophage diameter, number of macrophages per microscopic field and quantification of the autofluorescence signal of macrophages.  In 5 out of 6 AR cases, a diffuse infiltration of autofluorescent cells with a mean diameter of 26.2±13.3μm, was recognized in all examined segments. The number of macrophages per microscopic field and their autofluorescence intensity were significantly higher in the AR group than in the non-AR group (p   In the lung transplant recipient group studied, our preliminary findings suggest that pCLE is able to detect an alveoloscopic pattern that might correlate with AR.
Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation.
Authors: Gabriele Buda, Valentina Maggini, Enrico Orciuolo, Sara Galimberti, Alessandro Martino, Fortunato Morabito, Roberto Barale, Anna Maria Rossi, Mario Petrini
Journal: Blood (2007)
INFESTATION BY BROAD TAPEWORM
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Effect of upper extremity training on respiratory muscle strength, activities of daily living and fatigue perception in patients with chronic obstructive pulmonary disease
Authors: Hulya Arikan, Ebru Calik-Kutukcu, Naciye Vardar-Yagli, Melda Saglam, Cigdem Oksuz, Deniz Inal-Ince, Tulin Duger, Sema Savci, Hulya Kayihan, Lutfi Coplu
Journal: European Respiratory Journal (2014)

Introduction and background: Because of the use of accessory respiratory muscles during arm exercises, contributions of ventilation reduces. There is limited study about the effects of upper extremity strength training on activities of daily living (ADL) in patients with COPD

Aim and objectives: The aim of this study was to investigate the effect of upper extremity strength training on respiratory muscle strength, ADL and fatigue perception in patients with COPD.

Methods:Seventeen COPD patients (mean FEV1= 45.9±14.6%) were included in the study. Respiratory muscle strength, ADL (ADL simulation test) and fatigue perception (Fatigue Severity Scale-FSS) were evaluated before and after training. Physiologic responses and number of cycles (erasing board, washing dishes, removing weights, inserting and removing lights) completed in 10 min during ADL test were recorded. Strength training was given to patients for 8 weeks.

Results: MIP values and number of cycles in ADL simulation test of patients were significantly increased with training (p=0.045, p=0.001 respectively).Dyspnea perception levels during ADL test and FSS scores were significantly reduced after training (p = 0.021, p=0.026 respectively).

Conclusions:Upper extremity muscle training increases inspiratory muscle strength and positively affects performance during ADLin patients with COPD. This type of training also decreases dyspnea perception during ADL and fatigue perception. Potentially positive effects of upper extremity training should be considered in pulmonary rehabilitation programs of patients who have difficulty because of dyspnea during ADL.
Case-Control Study of Hodgkin's Disease. II. Herpesvirus Group Antibody Titers and HL-A Type&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Brian E. Henderson, Ruth Dworsky, Herman Menck, Barbara Alena, Werner Henle, Gertrude Henle, Paul Terasaki, Guy R. Newell, William Rawlings, B. Kay Kinnear
Journal: JNCI Journal of the National Cancer Institute (1973)

Geometric mean antibody titers to the Epstein-Barr virus were elevated in patients with 3 histologic subtypes of Hodgkin's disease and were normal in patients with the lymphocyte predominance subtype. Antibody titers to 3 other herpesvlruses were normal. Patients with Hodgkin's disease had an increased frequency of HL-A1.
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases
Authors: W. J. Allard, J. Matera, M. C. Miller, M. Repollet, M. C. Connelly, C. Rao, A. Stopeck, L. V. M. M. Terstappen
Journal: Journal of Clinical Oncology (2004)

9552 Background: The number of circulating tumor cells (CTC) in carcinoma patients may provide diagnostic and prognostic information to guide selection and monitor efficacy of therapies. This requires a standardized assay that is accurate and reproducible. Previous studies have demonstrated that CTC can be detected in peripheral blood of cancer patients, but a systematic survey of the prevalence of CTC in healthy subjects, patients with non-malignant diseases and a wide range of carcinomas is needed to establish a foundation for clinical implementation of this technology. Methods: We developed the CellSearch assay to accurately and reproducibly enumerate CTC in 7.5 ml of blood. The assay is based on immunomagnetic enrichment and fluorescent labeling of CTC followed by enumeration on a four color semi-automated fluorescence microscope. Blood from 145 healthy women, 199 women with non-malignant diseases and 1082 patients with a variety of metastatic carcinomas was tested for the presence of CTC. Results: Blood samples spiked with tumor cells were used to establish accuracy, reproducibility and linearity of the test. Recovery of spiked cells was ≥ 85% with a CV of 9.4% at a spike of 258 cells and 15.8% at a spike of 47 cells. The assay was linear over the tested range of 4 –1000 cells (r2=0.99). CTC in 344 healthy and non-malignant subjects were extremely rare with only one sample with > 1 cell/7.5 mL. In metastatic carcinoma patients CTC ranged from 0 to 3677 /7.5 mL (mean 32 ± 218). In 36% of the 1082 samples 2 or more CTC were present in 7.5 ml of blood. In 181 prostate cancer patients ≥2 CTC were detected in 57%, in 331 breast cancer patients 37%, in 47 ovarian cancers 36%, in 259 colorectal cancers 30%, and in 149 lung cancer patients 22%. Conclusions: The CellSearch assay is a reliable highly sensitive assay that can be used to explore the clinical utility of CTC in carcinomas. CTC are present in various metastatic carcinomas with a wide range of frequencies. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Immunicon Corp. Immunicon Corp. Immunicon Corp.
Frontline docetaxel (T)/ capecitabine (X) combination therapy in patients (pts) with metastatic breast cancer (MBC): A phase II study
Authors: J. H. Chun, H. G. Lee, E. S. Lee, E. Kim, J. H. Oh, J. Ro
Journal: Journal of Clinical Oncology (2004)

778 Background: TX demonstrated synergy presumably due to T-induced upregulation of thymidine phosphorylase in preclinical studies. In anthracycline pretreated MBC patients (pts), a phase III trial showed TX had better RR (42 vs 30%), longer TTP (6.1 vs 4.2 mo) and OS compared with T. A phase II study was performed to assess the efficacy and safety of TX as frontline therapy for MBC. Method: Pts with measurable MBC and ECOG PS 0–2 without prior chemotherapy for MBC were eligible. T (75mg/m2, iv D1) and X (1,000mg/m2 po BID for 2 wks) were administered q 3 wks until tumor progression or unacceptable toxicity. Routine medication for T was given. Results: 36 pts (23 recurrent and 13 stage IV disease) with median age 51 yrs (range, 28 –60 yrs) were entered in this study. All pts had PS 0 or 1. DFI of recurrent pts was 26 mo (range, 5–94 mo). ER+ was 38.9%, PR+, 30.6%, HER2 3+, 16.7%. Disease sites were breast in 13, LN 26, chest wall 3, bone 12, lung 15, and liver 14 pts. 26.0% of the pts received anthracyline-based regimen and 69.5% CMF regimen. A total of 179 cycles was given with median 6 (range, 1–10). 28 pts had G3/4 neutropenia, 1 febrile neutropenia, 4 G3 hand- foot syndrome, 26 G2 nail change. 3 pts were lost for follow up after 1 cycle. With median follow up of 34 wks (range, 7–65 wks), median survival has not been reached. There were 3 CR and 17 PR with overall RR of 55.6%. Pts with prior adjuvant chemotherapy had lower RR than pts without (40.9% vs 78.6%, p=0.04). All 3 CR and 15 PR were observed in anthracycline-naive pts. Median response duration was 31 wks (range, 4+ to 58+ wks) and median TTP was 35 wks (range 6 to 65 wks +). Mean relative dose intensity (DI) was 84 % for T and 73 % for X. Conclusion: TX combination is an efficacious frontline-therapy with high RR and prolonged response duration particularly in pts with anthracycline naive MBC, with moderate toxicity profiles. T 60–65mg/m2 D1 with X 800mg/m2, BID for 14days, q 3wks are considered an optimal combination dose in MBC (Supported in part by Aventis Pharma and Roche Korea). No significant financial relationships to disclose.
Vitamin A Contents of Rat Intestinal Epithelium and Jejunal Mucinous Adenocarcinoma 2 3
Authors: P. Ramnathan Sundaresan, Luigi M. De Luca
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Vitamin A Contents of Rat Intestinal Epithelium and Jejunal Mucinous Adenocarcinoma Get access P. Ramnathan Sundaresan, P. Ramnathan Sundaresan Search for other works by this author on: Oxford Academic PubMed Google Scholar Luigi M. De Luca Luigi M. De Luca 6 6Address reprint requests to Dr. De Luca. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 6, June 1977, Pages 1643–1645, https://doi.org/10.1093/jnci/58.6.1643 Published: 01 June 1977 Article history Received: 30 June 1976 Accepted: 07 December 1976 Published: 01 June 1977
Fat, Calories, and Cancer
Authors: Yves A. DeClerck
Journal: Cancer Research (2016)

See related article by Lavick and Baumann, [Cancer Res 1943;3:749–56][1] .

Visit the Cancer Research 75th Anniversary [timeline][2].

In this issue of Cancer Research , a seminal article from Lavick and Baumann published in the Journal in 1943 is highlighted in celebration of the Journal's 75th
When I use a word ...: Fin de siecle countdown
Authors: J. Aronson
Journal: BMJ (1999)

So, does the new millennium really begin on 1 January 2000, which is when everyone will celebrate it, or on 1 January 2001, as Arthur C Clarke told us it would? I don't think that it matters. If you don't like to think of the year 2000 as the start of the third millennium, just think of it as the start of the two thousands. This is, after all, the Italian way. For instance, trecento art and literature is from the 1300s—that is, the …
A device for real-time, intraoperative margin assessment in breast-conservation surgery (BCS) of ductal carcinoma in situ (DCIS).
Authors: M. Thill, K. Roeder, D. Fischer, N. Buendgen, K. Diedrich, C. Dittmer
Journal: Journal of Clinical Oncology (2010)

e11080 Background: A sufficient margin assessment when excising a DCIS of the breast is difficult. Frozen section is unreliable and intraoperative radiography of the specimen gives only information about the size of the noticed lesion or the microcalcifications. This trial was conducted to study the benefit of a novel device (MarginProbe, Dune Medical Devices. Ltd.) in intraoperative margin assessment for BCS of DCIS and the associated reduction in reoperations. Methods: A multicenter, single arm study was conducted to determine the added benefit of the device use. The device was used as an adjunctive tool to the current practice. The surgeon received real time device output and reacted surgically intraoperatively. Based on the permanent histology report outcome, the added benefit of device use is demonstrated. Analyzed were the first 15 pts. enrolled in our institution (Sept. 2009–Jan. 2010). This preliminary analysis was done because of the excellent results. Results: Patients who benefit from MarginProbe were analyzed (8/15). Device use was associated with improved correct surgical reaction, defined as patients in which all histologically detected positive margins on the main specimen were identified by the device and resected intraoperatively. In 50 % (4/8, 50%) a repeat operation was avoided, in 2 pts. the device did not detect all positive margins (2/8, 25%) and two patients turned out to have invasive cancer (2/25%). Conclusions: Intraoperative use of the MarginProbe for positive margin detection is safe, fast and effective in BCS and decreases the rate of repeat operations by 50%. No significant financial relationships to disclose.
Charity condemns attack on Afghan hospital as “war crime”
Authors: Adrian O’Dowd
Journal: BMJ (2015)

An international medical humanitarian charity has condemned an aerial attack on a hospital on 3 October in Afghanistan that left 22 people dead and many others injured.

Medecins Sans Frontieres (MSF) has now demanded an independent investigation into the attack on the MSF run Kunduz trauma hospital, which it claimed was carried out by US led NATO forces together with Afghan forces. A US military investigation into the incident is now under way in coordination with the Afghan government.

The charity said that the hospital had come under attack in the early hours of Saturday 3 October from a series of aerial bombing raids that hit the central hospital building, which housed the intensive care unit, …
Motivating an underserved African American population to seek breast and prostate cancer screening utilizing a coalition of 11 community-based organizations.
Authors: D. C. Hunter, J. Brustrom, K. Garrett
Journal: Journal of Clinical Oncology (2010)

e16556 Background: African Americans (AAs) suffer a higher mortality rate due to breast and prostate cancer compared to Caucasians for multiple reasons. There is evidence that partnering with trusted community-based organizations can successfully motivate underserved AA populations to seek preventive services. Methods: The Sacramento Community Cancer Coalition was formed to increase the number of underserved AA individuals in the Sacramento, California area receiving age-appropriate breast and prostate cancer screening. The first Coalition event was a one-day health fair at a student-run free clinic in Sacramento in which breast and prostate cancer screening examinations were offered free of charge. Marketing efforts targeting AAs were conducted before the health fair. Attendees were provided an interview assessing background/demographic information, beliefs about cancer screening, reasons for being screened, and knowledge about cancer risk factors. Results: Interviewees were racially and ethnically diverse- 46% AA, 19% Caucasian, 19% Hispanic/Latina, 8% Asian, 8% Other. The percentage of AA individuals who attended the health fair was higher than the percentage of AA individuals attending the clinic during the 9 months preceding the fair (46% vs. 22% of attendees at each time point, respectively Z = 2.5, p < 0.05), suggesting that the health fair was successful at encouraging AAs to attend the event. Preliminary analysis of the interview data revealed few differences between AA attendees and attendees of other race/ethnicities in terms of reasons for being screened for cancer, beliefs about cancer screening, and knowledge of cancer and cancer risk factors. Knowledge of cancer risk factors was relatively poor among all attendees, regardless of race/ethnicity. Conclusions: The collaborative model was successful in attracting a hard to reach underserved African American population. No significant financial relationships to disclose.
Neoadjuvant therapy for resectable pancreatic adenocarcinoma: An interim report of a prospective randomized study.
Authors: M. Di Marco, M. Macchini, R. di Cicilia, S. Vecchiarelli, R. Casadei, E. Barbieri, L. Calculli, M. A. Pantaleo, G. Biasco
Journal: Journal of Clinical Oncology (2010)

e14604 Background: We compare neoadjuvant chemoradiation therapy plus surgery versus surgery alone in patients with resectable pancreatic adenocarcinoma (RPA) in a prospective, controlled, randomized study. The primary end-point was to evaluate the R0 resection rate in the two groups and secondary was safety/efficacy of neoadjuvant therapy, postoperative mortality, morbidity, lymph node-ratio and pTNM stage. Methods: Patients with RPA were randomized to receive either neoadjuvant therapy plus surgery (group A) or surgery alone (group B). In group A, patients received gemcitabine (1,000 mg/m2) on days 1,8 every 21, followed by radiation therapy (45 Gy plus boost of 9 Gy) plus gemcitabine 50 mg/m2 biweekly, for 6 weeks. A CT scan restaging was performed before surgery. Results: From March 2007 we enrolled 19 consecutive patients (9 male and 8 female). Seventeen among the eligible patients 7 (41%) were randomized in group A and 10 (59%) in group B. After neoadjuvant therapy one patient (14.3%) had a progression of disease, 4 had stable disease (57.2%) and 2 (28.5%) had partial response. Consequently 6 patients in group A, underwent surgery (85.7%) and 4 of these (66.6%) experienced a successful resection. In group B surgical resection was performed in 9 patients (90%). R0 resection rate was 75% (3/4) in group A and 30% (2/9) in group B without statistically significant difference (p = 0.217). Regarding to safety myelotoxicity (57.1%), asthenia, weight loss (28.5%) and gastrointestinal toxicity (57.1%) were reported in group A patients. Overall postoperative mortality was 1 (11.1%) without significantly difference in the two groups (p = 1.000); overall postoperative morbidity was 0% in group A and 44.4% in group B (p = 0.093). There was no difference regarding pTNM stage (p = 0.364). Mean total number of lymph node removed with surgical specimen was similar in the two group (A: 29.5 vs. B: 27, p = 0.636). Mean number of lymph node metastasis was lesser in group A (p = 0.035). Conclusions: Despite the small number of patients, preliminary data suggest that neoadjuvant chemoradiation therapy plus surgery increases the R0 resection rate, reduces the lymph nodes ratio and allows a better postoperative course. No significant financial relationships to disclose.